Aggressive variants of prostate cancer - are we ready to apply specific treatment right now?

Prostate cancer (PC) is the second most common malignancy in the western world [1]. For many years, the mainstay treatment for metastatic PC has been androgen deprivation therapy (ADT) [2]. However, the therapeutic landscape of metastatic hormone-sensitive PC (mHSPC) has changed substantially over the past years, with significantly improved survival following early combination of ADT with docetaxel or abiraterone acetate [3,4]. Eventually, treatment resistance of PC cells will evolve until a castration-resistant stage is reached [5].

Source: Cancer Treatment Reviews - March 10, 2019 Category: Cancer & Oncology Authors: Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Giorgio Gandaglia, Alberto Briganti, Pieter de Visschere, Romain Mathieu, Massimo Valerio, Roderick van den Bergh, Piet Ost, Cristian Mirvald, Derya Tilki, Guillaume Ploussard, Cristian Source Type: research